The NHS says only 8,300 doses of the imvanex vaccine are available nationwide, and are expected to run out in 10 to 20 days, but up to 250,000 are needed to be administered to people, the NHS agency said. everyone who joins In the United States, equally serious, the FDA ordered Tuesday (August 9) that the JYNNEOS-coded monkeypox vaccine could be administered subcutaneously instead to address the problem of inadequate vaccines. Currently there are 441,000 doses, but the new method will expand to 2.2 million doses. Bavarian Company Nordic manufacturers fear US changing injection methods fears it is unsafe.
British media The Guardian reported yesterday (10 Aug) that the monkeypox vaccine stock (monkeypox) The vaccine is running out in the UK, prompting warnings that monkey pox could become endemic.
British media pointed out The UK is likely to run out of its imvanex smallpox vaccine within a few weeks before facing a delivery delay that will occur around the end of September.
An internal memo from the British National Health Service, the NHS, reveals that nationwide, there are currently only 8,300 doses of the Bavarian Nordic monkey pox vaccine Imvanex.
Dr. Clare Dewsnap, president of the British Association for Sexual Health and HIV (BASHH) commented that
“Based on current estimates, there are only 8,300 vaccine doses with 5,000 doses for London at the peak of demand. As a result, it indicates that the remaining vaccines will run out within 10 to 20 days, creating a gap in supply until supplies arrive in September.”
According to Reuters, The new lot to be delivered is 100,000 doses.
and added that “There is no urgent solution to acquiring more vaccines to avoid supply gaps. We risk the disease spreading across the country and becoming an endemic public health challenge.”
BASHH estimates the UK needs to have 250,000 doses of the monkey pox vaccine, enough to be given to the 125,000 people it targets. Still, the British government has only purchased 100,000 doses to date.
The number of monkeypox infections in the UK on Thursday was 2,859 cases, mostly among MSM. Globally, there are about 30,000 cases and a total of nine deaths.
The monkey pox vaccine is produced by the Danish company Bavarian Nordic. It’s called Imvanex, in Europe it’s known as Jynneos in the US and Imvamune in Canada, according to science.org.
Reuters reported today (11) that bavarian pharmaceutical company The Nordics have expressed concern about the US Food and Drug Administration’s approval to change the company’s JYNNEOS-coded chickenpox vaccine subcutaneously to address the problem of inadequate vaccines. Total 441,000 doses, but the new subcutaneous injection method will expand to 2.2 million doses.
Earlier on Thursday, the US declared smallpox a public emergency.
NPR reported Tuesday (9) that On Tuesday afternoon, federal health officials announced a decision to allow inter-dermal vaccination instead of the old fat-associated injection. 1 in 5 full dose for each patient
US FDA Issues Emergency Order for New Dosage and New Injection Methods US Food and Drug Administration FDA Director Dr. Robert M. Califf said in a statement on the matter:
“In recent weeks, monkeypox has continued to spread at a rate that makes it clear that our current vaccine supply cannot meet current needs,” he added. “This will increase the total number of doses available by 5 times.”
NPR pointed out that despite the change in injection methods, recipient patients will still need two doses of the monkey pox vaccine, which in addition to the adult population, the FDA has also given the opportunity to allow younger people. 18-year-olds thought to be at risk can be vaccinated, of which 1.6 to 1.7 million are at risk. However, only 1.1 million doses of the vaccine are in stock due to expiration issues of the vaccine being kept and the delay in ordering more of those doses.
Some 670,000 doses of the monkey pox vaccine (JYNNEOS) have been delivered to US states and territories.